Intrapleural administration of sustained-release basic fibroblast growth factor in patients with chronic obstructive pulmonary disease accompanied by pneumothorax

Intrapleural administration of sustained-release basic fibroblast growth factor in patients with chronic obstructive pulmonary disease accompanied by pneumothorax - Intrapleural administration of sustained-release basic fibroblast growth factor in patients with chronic obstructive pulmonary disease accompanied by pneumothorax

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004276

Enrollment

Registered

2010-12-01

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease accompanied by pneumothorax

Interventions

Sustained-release basic fibroblast growth factor (2.5 mg) diluted with fibrin glue solution is administrated to patients with chronic obstructive pulmonary disease accompanied by pneumothorax through

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic obstructive pulmonary disease accompanied by pneumothorax

Exclusion criteria

Exclusion criteria: Patients with malignant tumors Patients with intrapleural bacterial infection Patients with allergy for gelatin Patients with past history of side effect by trafermin

Design outcomes

Primary

Measure	Time frame
Spirometry Blood gas examination Hugh-Jones score Performance statis Hospital stay Recurrence free survival Overall survival CT value of lung	—

Countries

Japan

Contacts

Public ContactTatsuya Yoshimasu

Wakayama Medical University Department of Thoracic and Cardiovascular Surgery

yositatu@wakayama-med.ac.jp073-447-2300

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026